Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
441-460 of 1,743 trials

Non-Small Cell Lung Cancer: DS-1062a Treatment Study

We are testing a new antibody-drug conjugate for patients with advanced non-small cell lung cancer. The study aims to see how effective it is and how individual responses may vary.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)Oncology

Advanced Breast Cancer: HER3-DXd Treatment Study

We are investigating a new drug for patients with inoperable advanced breast cancer who have progressed after previous treatment. The study aims to understand its safety and effectiveness, both alone and in combination with other therapies.

HER2-positive and HER2-low Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

IgM Monoclonal Gammopathy: Zanubrutinib and Rituximab Study

We are investigating whether a new treatment combining Zanubrutinib with Rituximab can improve nerve function in patients with IgM monoclonal gammopathy and related nerve damage. The study will also look at safety and how well patients tolerate the treatment.

Anti-MAG Neuropathy>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyNeurology

Obesity Surgery: Opioid Sparing Care Pathway

We are studying a new pain management approach for patients undergoing obesity surgery to see if it helps reduce opioid use and improve recovery. This may lead to better health outcomes and less reliance on pain medications.

Postoperative PainObesity>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngology

Osteoporosis Treatment: The OPTIMIST Study on Romosozumab

We are exploring the best ways to use romosozumab for osteoporosis treatment. Additionally, we’re investigating if it has any impact on insulin sensitivity.

Osteoporosis>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine

TAK-881 for Primary Immunodeficiency Diseases

We are studying the long-term safety and tolerability of TAK-881 in individuals with Primary Immunodeficiency Diseases. This trial will also assess how well the treatment works and its effects on patients' quality of life.

Primary Immunodeficiency Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyInfectious Diseases

Diabetes Foot Ulcers: Mesenchymal Stem Cells Study

We are exploring whether mesenchymal stem cells can help heal foot ulcers in people with diabetes. This early study aims to assess the safety and potential benefits of this treatment.

Diabetic Foot Ulcer>2 yearsSafety phase (I)Efficacy phase (II)DermatologyDiabetology

Persistent Atrial Fibrillation: Cryoballoon vs. Medication

We are studying whether early treatment with a cryoballoon is more effective than antiarrhythmic drugs for people with persistent atrial fibrillation. The trial also looks at how these treatments affect quality of life and healthcare needs.

Persistent Symptomatic Atrial Fibrillation>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiology

Systemic Sclerosis: Anifrolumab Treatment Study

We are investigating whether Anifrolumab can improve symptoms and lung function in adults with systemic sclerosis. This study compares the new treatment to a placebo to see how well it works.

Systemic SclerosisImmune System DiseasesInterstitial Lung Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Severe Systemic Sclerosis: Stem Cell Treatment Study

We are investigating the safety of a new stem cell therapy for people with severe systemic sclerosis. The study aims to see if this treatment can improve skin and lung function.

Systemic Sclerosis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesInternal MedicineRheumatology

Multiple Myeloma: BMS-986453 Treatment

We are testing a new drug for individuals with relapsed or refractory multiple myeloma. The goal is to understand its safety and how it may help manage their condition.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Small Cell Lung Cancer: BI 764532 with Chemotherapy

We are testing how well different doses of BI 764532 are tolerated by people with small cell lung cancer when combined with chemotherapy. This study aims to find the safest and most effective dose.

Extensive Stage Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Advanced Small Cell Lung Cancer: BI 764532 Study

We are testing how well different doses of a new medication work with standard care for people with advanced small cell lung cancer. This study aims to see how well patients tolerate the treatment.

Extensive-Stage Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Juvenile Psoriatic Arthritis: Risankizumab Study

We are studying a new treatment called risankizumab for children aged 5 to 17 with active juvenile psoriatic arthritis. The goal is to see if it is safe and effective compared to an existing medication.

Juvenile Psoriatic Arthritis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyPediatricsRheumatology

DIPG Treatment Study: ONC201 vs. Everolimus

We are testing a new drug, ONC201, for children with newly diagnosed DIPG and related tumors. The goal is to see if it helps improve survival and progression-free time compared to standard treatment.

Brain Stem Glioma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Follicular Lymphoma: Mosunetuzumab and Zanubrutinib Study

We are investigating a combination of two medications for patients with relapsed or refractory follicular lymphoma. The goal is to see if this treatment improves outcomes and safety compared to existing options.

Follicular Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematology

Gastric Cancer: Dostarlimab Immunotherapy Study

We are exploring a new treatment approach for patients with localized gastric cancer to see if delaying surgery while using Dostarlimab can be effective. The study aims to evaluate patient responses and safety over time.

Metastatic Gastric Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology

Colorectal Cancer: Reduced Dose Chemotherapy for Older Patients

We are studying whether a lower dose of chemotherapy is as effective as the standard dose for older patients with advanced colorectal cancer. This may help improve quality of life and reduce severe side effects.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Achondroplasia: Infigratinib for Children

We are investigating a new medication, infigratinib, for children aged 3 to under 18 with achondroplasia. The study aims to see if it helps improve growth and body proportions while ensuring safety.

Achondroplasia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOrthopedics and TraumatologyPediatrics

Juvenile Idiopathic Arthritis: Baricitinib Study

We are investigating whether the medication baricitinib is safe and effective for children and teens aged 1 to 17 with juvenile idiopathic arthritis. This study aims to improve treatment options for this condition.

Juvenile Idiopathic Arthritis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology